Roman Viktorovich Rozhivanov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Roman Viktorovich Rozhivanov has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Elena N. Andreeva
Federal State Budgetary Educational Institution of Higher Education «Russian University of Medicine» of the Ministry of Health of Russia
19 shared publications - Nataliya G. Mokrysheva
Endocrinology Research Centre, 117292 Moscow, Russia
19 shared publications - E. R. Rozhivanova
Endocrinology Research Centre
18 shared publications - Marina Vladimirovna Shestakova
Endocrinology Research Centre, 117292 Moscow, Russia
14 shared publications G. A. Mel’nIchenko
«Endocrinology research center» State funded research facility of the Ministry of Health of Russian Federation
12 shared publications- G. A. Melnichenko
Endocrinology Research Centre
11 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (4) , 106-114
The unbearable versatility of endocrine aging
Ageing is multifactorial, genetically and epigenetically programmed biological process. Nowadays ageing is acknowledged as extremely actual scientifical, social and demographical problem. Despite the evidence of interactions between ageing and accumulation of endocrine disruptions, the last 150 years of variegated searches for potential endocrine “elixir of lon gevity” brought contradictive, mutually exclusive and even discouraging results. Fortunately, the discovery of referent lab oratory intervals of hormonal blood levels among elderly people improved the overall situation. Traditional treatment of endocrine hormonal deficiency with replacement therapy does not lead to rejuvenation but to potential damage. That’s why it is more accepted to interpret hormonal changes among elderly people not only as aging but specific adaptation for “successful ageing”. The present review contains modern datas about endocrine ageing of thyroid gland, adrenal glands (hy percorticism, adrenopause), pituitary gland (somatopause, hypoprolactinemia), male (andropause) and female (menopause, hyperandrogenism) hypogonadism.
- 8 September 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (4) , 106-114
Open AccessThe unbearable versatility of endocrine aging
Ageing is multifactorial, genetically and epigenetically programmed biological process. Nowadays ageing is acknowledged as extremely actual scientifical, social and demographical problem. Despite the evidence of interactions between ageing and accumulation of endocrine disruptions, the last 150 years of variegated searches for potential endocrine “elixir of lon gevity” brought contradictive, mutually exclusive and even discouraging results. Fortunately, the discovery of referent lab oratory intervals of hormonal blood levels among elderly people improved the overall situation. Traditional treatment of endocrine hormonal deficiency with replacement therapy does not lead to rejuvenation but to potential damage. That’s why it is more accepted to interpret hormonal changes among elderly people not only as aging but specific adaptation for “successful ageing”. The present review contains modern datas about endocrine ageing of thyroid gland, adrenal glands (hy percorticism, adrenopause), pituitary gland (somatopause, hypoprolactinemia), male (andropause) and female (menopause, hyperandrogenism) hypogonadism.
- Open Access
- 18 July 2026
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 23 (2) , 4-12
Evaluation of the effect of androgen replacement therapy using transdermal testosterone in males with obesity and hypogonadism
BACKGROUND: Being an indication for androgen replacement therapy, male hypogonadism is often associated with obesity. Therefore, assessing the impact of testosterone replacement therapy (TRT) on obesity is relevant. AIMS: To evaluate the impact of transdermal TRT on obesity and quality of life (QOL) in males with hypogonadism. MATERIALS AND METHODS: A comparative, randomized, prospective study enrolled 156 hypogonadal and obese males aged 39 [34; 44] years (the comparison group had no concurrent intervention). Study participants were randomly assigned 1 of the 2 groups by matching appropriate pairs. Group 1 consisted of males receiving transdermal TRT, while Group 2 consisted of patients not receiving androgen therapy but undergoing obesity treatment through diet and lifestyle modification. The observation period was 12 months. A retrospective comparison was also performed on patient subgroups within Group 2, based on whether their hypogonadism was eliminated or persisted. The procedures included collecting patient anamnesis, conducting a physical examination to determine body mass index, administering a questionnaire regarding androgen deficiency symptoms, and assessing total testosterone levels. The Mann–Whitney U-test, Wilcoxon test, and χ² with Yates' correction were employed for group comparisons. A p-value below 0.05 was deemed statistically significant. Multiple comparisons were adjusted using the Bonferroni correction. RESULTS: The groups were comparable regarding the parameters examined at the study's outset. Most of the parameters observed showed statistically significant alterations in both groups 1 and 2, except for hematocrit and hemoglobin levels in group 2. Patients receiving TRT after 12 months from their inclusion into the study had a statistically significantly higher level of total testosterone and lesser severity of androgen deficiency symptoms. When assessing the magnitude of changes in the studied parameters, it was found that patients receiving TRT were characterized by a statistically significantly more pronounced decrease in body weight (mean difference -4.0% (95% CI -5.2; -2.7, р50%) were observed in 23% of men on TRT and 12% of patients without hypogonadism therapy, p=0.098 (χ² with Yates' correction). Hemoglobin elevations above the reference value (>160 g/L) were detected in 37% and 15% of males on TRT and without hypogonadism therapy, respectively (p=0.003; χ² with Yates' correction). No increases in hematocrit or hemoglobin levels requiring discontinuation of TRT were observed. CONCLUSIONS: Treatment of hypogonadism using TRT has a positive effect on weight loss in obese males. Furthermore, normalization of testosterone levels leads to a reduction in androgen deficiency symptoms, accompanied by an improvement in quality of life (QOL). Hypogonadism cessation with obesity treatment alone (without the use of TRT) is possible in 41% (95% CI 30.1-53.3) of cases, provided clinically significant weight loss is achieved. Since most respondents achieved normalization of total testosterone levels within the first 6 months, this allows timely initiation of TRT to those patients who have not achieved stable normalization of total testosterone levels within a specified time.
- 18 July 2026
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 23 (2) , 4-12
Open AccessEvaluation of the effect of androgen replacement therapy using transdermal testosterone in males with obesity and hypogonadism
BACKGROUND: Being an indication for androgen replacement therapy, male hypogonadism is often associated with obesity. Therefore, assessing the impact of testosterone replacement therapy (TRT) on obesity is relevant. AIMS: To evaluate the impact of transdermal TRT on obesity and quality of life (QOL) in males with hypogonadism. MATERIALS AND METHODS: A comparative, randomized, prospective study enrolled 156 hypogonadal and obese males aged 39 [34; 44] years (the comparison group had no concurrent intervention). Study participants were randomly assigned 1 of the 2 groups by matching appropriate pairs. Group 1 consisted of males receiving transdermal TRT, while Group 2 consisted of patients not receiving androgen therapy but undergoing obesity treatment through diet and lifestyle modification. The observation period was 12 months. A retrospective comparison was also performed on patient subgroups within Group 2, based on whether their hypogonadism was eliminated or persisted. The procedures included collecting patient anamnesis, conducting a physical examination to determine body mass index, administering a questionnaire regarding androgen deficiency symptoms, and assessing total testosterone levels. The Mann–Whitney U-test, Wilcoxon test, and χ² with Yates' correction were employed for group comparisons. A p-value below 0.05 was deemed statistically significant. Multiple comparisons were adjusted using the Bonferroni correction. RESULTS: The groups were comparable regarding the parameters examined at the study's outset. Most of the parameters observed showed statistically significant alterations in both groups 1 and 2, except for hematocrit and hemoglobin levels in group 2. Patients receiving TRT after 12 months from their inclusion into the study had a statistically significantly higher level of total testosterone and lesser severity of androgen deficiency symptoms. When assessing the magnitude of changes in the studied parameters, it was found that patients receiving TRT were characterized by a statistically significantly more pronounced decrease in body weight (mean difference -4.0% (95% CI -5.2; -2.7, р50%) were observed in 23% of men on TRT and 12% of patients without hypogonadism therapy, p=0.098 (χ² with Yates' correction). Hemoglobin elevations above the reference value (>160 g/L) were detected in 37% and 15% of males on TRT and without hypogonadism therapy, respectively (p=0.003; χ² with Yates' correction). No increases in hematocrit or hemoglobin levels requiring discontinuation of TRT were observed. CONCLUSIONS: Treatment of hypogonadism using TRT has a positive effect on weight loss in obese males. Furthermore, normalization of testosterone levels leads to a reduction in androgen deficiency symptoms, accompanied by an improvement in quality of life (QOL). Hypogonadism cessation with obesity treatment alone (without the use of TRT) is possible in 41% (95% CI 30.1-53.3) of cases, provided clinically significant weight loss is achieved. Since most respondents achieved normalization of total testosterone levels within the first 6 months, this allows timely initiation of TRT to those patients who have not achieved stable normalization of total testosterone levels within a specified time.
- Open Access
- 26 April 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- No. 1,p. 18-25
Correction of male hypogonadism caused by anabolic steroid use
The widespread use of anabolic steroids (AS) in sports and recreational fitness has led to an increase in the frequency of iatrogenic hypogonadotropic hypogonadism among men. This condition, characterized by the suppression of the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback, manifests as severe testosterone deficiency, impaired spermatogenesis, and a wide range of negative clinical symptoms. This review systematizes current data on the methods for correcting AAS induced hypogonadism. Unlike similar works, the emphasis is placed on the pathogenetic rationale for choosing a therapeutic strategy based on clearly defined clinical goals: rapid relief of symptoms versus restoration of fertility. It provides a detailed analysis not only of classical testosterone replacement therapy but also of methods aimed at restoring endogenous steroidogenesis and spermatogenesis: therapy with gonadotropins and selective estrogen receptor modulators. Particular attention is paid to prognostic factors for treatment success, including the duration and nature of prior AAS use. Based on the analyzed data, a systematic approach to patient management is proposed, emphasizing the need for treatment individualization. The review also contains a assessment of the potential role of selective androgen receptor modulators (SARM) and an analysis of the likelihood of spontaneous recovery of HPG axis function.
- 26 April 2026
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- No. 1,p. 18-25
Open AccessCorrection of male hypogonadism caused by anabolic steroid use
The widespread use of anabolic steroids (AS) in sports and recreational fitness has led to an increase in the frequency of iatrogenic hypogonadotropic hypogonadism among men. This condition, characterized by the suppression of the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback, manifests as severe testosterone deficiency, impaired spermatogenesis, and a wide range of negative clinical symptoms. This review systematizes current data on the methods for correcting AAS induced hypogonadism. Unlike similar works, the emphasis is placed on the pathogenetic rationale for choosing a therapeutic strategy based on clearly defined clinical goals: rapid relief of symptoms versus restoration of fertility. It provides a detailed analysis not only of classical testosterone replacement therapy but also of methods aimed at restoring endogenous steroidogenesis and spermatogenesis: therapy with gonadotropins and selective estrogen receptor modulators. Particular attention is paid to prognostic factors for treatment success, including the duration and nature of prior AAS use. Based on the analyzed data, a systematic approach to patient management is proposed, emphasizing the need for treatment individualization. The review also contains a assessment of the potential role of selective androgen receptor modulators (SARM) and an analysis of the likelihood of spontaneous recovery of HPG axis function.
- 14 February 2026
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 22 (4) , 306-309
The effect of bariatric surgery on testosterone production in men
BACKGROUND : Male hypogonadism is associated with obesity; therefore, it is of interest to evaluate the impact of bariatric surgery – one of the most effective methods for reducing adipose tissue mass on testosterone production. AIM : Evaluation of the effect of bariatric surgery on testosterone production in men. MATERIALS AND METHODS : A solid prospective observational single-center interventional study included men with obesity who underwent bariatric surgery at the National Medical Research Center for Endocrinology of the Ministry of Health of the Russian Federation between January 2022 and August 2024. Dynamic assessment of body weight, body mass index, and total testosterone levels was performed. Group comparisons were made using nonparametric methods. Differences were considered statistically significant at p < 0.05. The Bonferroni correction was applied for multiple comparisons. RESULTS : A statistically significant reduction in body weight, amounting to -30.7 [-32.8; -27.2]% from baseline, was accompanied by a statistically significant increase in testosterone levels of 6.7 [4.2; 11.4] nmol/L. Hypogonadism was resolved in 56% (95% CI 31; 79) of men. Patients who achieved eugonadism had a statistically significantly higher baseline total testosterone level of 8.2 [7.3; 8.7] nmol/L compared to men with persistent hypogonadism — 5.5 [3.7; 6.5] nmol/L, p=0.005. There were no complications from bariatric surgery. CONCLUSION : The use of bariatric surgery leads to increased testosterone production and reduced frequency of hypogonadism in men.
- 14 February 2026
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 22 (4) , 306-309
The effect of bariatric surgery on testosterone production in men
BACKGROUND : Male hypogonadism is associated with obesity; therefore, it is of interest to evaluate the impact of bariatric surgery – one of the most effective methods for reducing adipose tissue mass on testosterone production. AIM : Evaluation of the effect of bariatric surgery on testosterone production in men. MATERIALS AND METHODS : A solid prospective observational single-center interventional study included men with obesity who underwent bariatric surgery at the National Medical Research Center for Endocrinology of the Ministry of Health of the Russian Federation between January 2022 and August 2024. Dynamic assessment of body weight, body mass index, and total testosterone levels was performed. Group comparisons were made using nonparametric methods. Differences were considered statistically significant at p < 0.05. The Bonferroni correction was applied for multiple comparisons. RESULTS : A statistically significant reduction in body weight, amounting to -30.7 [-32.8; -27.2]% from baseline, was accompanied by a statistically significant increase in testosterone levels of 6.7 [4.2; 11.4] nmol/L. Hypogonadism was resolved in 56% (95% CI 31; 79) of men. Patients who achieved eugonadism had a statistically significantly higher baseline total testosterone level of 8.2 [7.3; 8.7] nmol/L compared to men with persistent hypogonadism — 5.5 [3.7; 6.5] nmol/L, p=0.005. There were no complications from bariatric surgery. CONCLUSION : The use of bariatric surgery leads to increased testosterone production and reduced frequency of hypogonadism in men.
- Open Access
- 5 November 2025
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (3) , 12-19
Methods of correction of hypogonadism syndrome in men and long-term results of drug treatment
Hypogonadism syndrome, characterized by testosterone deficiency, negatively affects the physical, metabolic and psychoemotional health of men. The main treatments for hypogonadism include androgen replacement and androgen stimulating therapy. Androgen replacement therapy, represented by transdermal and injectable forms of testosterone, effectively restores testosterone levels, improves sexual function, muscle mass, bone mineral density and metabolic parameters. However, it suppresses spermatogenesis, which limits its use in men planning fatherhood. Androgen stimulating therapy, including gonadotropins, antiestrogens and aromatase inhibitors, stimulates the production of endogenous testosterone and spermatogenesis. Gonadotropins demonstrate high efficacy, but their long-term use is complicated by the need for frequent injections and the lack of long-term results. The long-term studies presented in the review confirm the safety and effectiveness of androgen replacement therapy, but data on androgen stimulating therapy are limited in follow-up time to a maximum of two years.
- 5 November 2025
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (3) , 12-19
Open AccessMethods of correction of hypogonadism syndrome in men and long-term results of drug treatment
Hypogonadism syndrome, characterized by testosterone deficiency, negatively affects the physical, metabolic and psychoemotional health of men. The main treatments for hypogonadism include androgen replacement and androgen stimulating therapy. Androgen replacement therapy, represented by transdermal and injectable forms of testosterone, effectively restores testosterone levels, improves sexual function, muscle mass, bone mineral density and metabolic parameters. However, it suppresses spermatogenesis, which limits its use in men planning fatherhood. Androgen stimulating therapy, including gonadotropins, antiestrogens and aromatase inhibitors, stimulates the production of endogenous testosterone and spermatogenesis. Gonadotropins demonstrate high efficacy, but their long-term use is complicated by the need for frequent injections and the lack of long-term results. The long-term studies presented in the review confirm the safety and effectiveness of androgen replacement therapy, but data on androgen stimulating therapy are limited in follow-up time to a maximum of two years.
- Open Access
- 1 November 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (5) , 483-489
Clinical and laboratory features of ankylosing spondylitis in men depending on testosterone levels
Objective – to study the incidence of hypogonadism in men with ankylosing spondylitis (AS) and evaluate its impact on AS and comorbidities. Materials and methods. The one-time continuous study included 124 men with AS who were undergoing inpatient treatment at the V.A. Nasonova Research Institute of Rheumatology. Patients were assessed for total testosterone levels and subsequently divided into subgroups with normal (≥12.0 nmol/l) and reduced levels. An intergroup comparison was carried out on the main indicators used in clinical rheumatological practice to assess the stage, activity and other medical and demographic characteristics of AS, as well as on concomitant diseases. A correlation analysis was performed between the level of total testosterone and some clinical and laboratory parameters. Results. The frequency of detected testosterone deficiency in the study group was 25.0%. With testosterone deficiency, a more frequent incidence of uveitis (45.2% vs 23.6%; p=0.022), as well as arterial hypertension (51.6% vs 30.1%; p=0.030) and type 2 diabetes mellitus (16.1% vs 4.3%; p=0.028). Testosterone deficiency was accompanied by higher levels of C-reactive protein (16.7 [3.2; 43.4] vs 5.0 [1.3; 17.4] mg/l; p=0.020), as well as higher frequency of increased ESR (45.2% vs 25.8%; p=0.043). There was a higher glucose level (5.75±1.19 vs 5.36±0.71 mmol/l; p=0.027) and more frequent impaired fasting glucose (25.8% vs 4.3%; pConclusion. A high incidence of hypogonadism in patients with AS has been revealed. Testosterone levels and the presence of hypogonadism were not associated with the stage and activity of AS, but testosterone deficiency was accompanied by a higher incidence of uveitis, higher laboratory indicators of AS activity, and the incidence of concomitant metabolic disorders.
- 1 November 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (5) , 483-489
Open AccessClinical and laboratory features of ankylosing spondylitis in men depending on testosterone levels
Objective – to study the incidence of hypogonadism in men with ankylosing spondylitis (AS) and evaluate its impact on AS and comorbidities. Materials and methods. The one-time continuous study included 124 men with AS who were undergoing inpatient treatment at the V.A. Nasonova Research Institute of Rheumatology. Patients were assessed for total testosterone levels and subsequently divided into subgroups with normal (≥12.0 nmol/l) and reduced levels. An intergroup comparison was carried out on the main indicators used in clinical rheumatological practice to assess the stage, activity and other medical and demographic characteristics of AS, as well as on concomitant diseases. A correlation analysis was performed between the level of total testosterone and some clinical and laboratory parameters. Results. The frequency of detected testosterone deficiency in the study group was 25.0%. With testosterone deficiency, a more frequent incidence of uveitis (45.2% vs 23.6%; p=0.022), as well as arterial hypertension (51.6% vs 30.1%; p=0.030) and type 2 diabetes mellitus (16.1% vs 4.3%; p=0.028). Testosterone deficiency was accompanied by higher levels of C-reactive protein (16.7 [3.2; 43.4] vs 5.0 [1.3; 17.4] mg/l; p=0.020), as well as higher frequency of increased ESR (45.2% vs 25.8%; p=0.043). There was a higher glucose level (5.75±1.19 vs 5.36±0.71 mmol/l; p=0.027) and more frequent impaired fasting glucose (25.8% vs 4.3%; pConclusion. A high incidence of hypogonadism in patients with AS has been revealed. Testosterone levels and the presence of hypogonadism were not associated with the stage and activity of AS, but testosterone deficiency was accompanied by a higher incidence of uveitis, higher laboratory indicators of AS activity, and the incidence of concomitant metabolic disorders.
- Open Access
- 14 September 2025
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (4) , 77-82
Restoration of ejaculate quality following androgen replacement and combined therapy for hypogonadism
BACKGROUND: To optimize androgen replacement therapy for male hypogonadism to improve reproductive prospects.AIM: To compare the effectiveness of restoring the quality of ejaculate in men receiving androgen replacement therapy (AZT) and patients receiving course combination therapy with testosterone and chorionic gonadotropin (AZT/HG).MATERIALS AND METHODS: In observational prospective study was included 53 men observed at The National Medical Research Center for Endocrinology and AZT (n=19) or AZT/HG (n=34) more than 5 years, followed by stimulating gonadotropin therapy. The qualitative parameters of ejaculate were evaluated in all patients. The basic level of statistical significance was pRESULTS: The patient groups were comparable in age, BMI, duration of therapy used, type of testosterone preparation, as well as the etiology of hypogonadism. Sperm concentration in the AZT group there was a statistically significant negative dynamics, while in the ART/HG group, there were no statistically significant differences in the dynamics of sperm concentration. Statistically significant differences in the value of sperm concentration change were revealed. In both groups was observed statistically significant negative dynamics for sperm motility and morphology. There were no statistically significant differences in the value of changes motility and sperm morphology in both studied groups.CONCLUSION: Course combination therapy with testosterone and chorionic gonadotropin is characterized by better results for sperm concentration restoration compared with androgenic replacement therapy. For the restoration of sperm motility and morphology both methods do not show satisfactory results.
- 14 September 2025
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (4) , 77-82
Open AccessRestoration of ejaculate quality following androgen replacement and combined therapy for hypogonadism
BACKGROUND: To optimize androgen replacement therapy for male hypogonadism to improve reproductive prospects.AIM: To compare the effectiveness of restoring the quality of ejaculate in men receiving androgen replacement therapy (AZT) and patients receiving course combination therapy with testosterone and chorionic gonadotropin (AZT/HG).MATERIALS AND METHODS: In observational prospective study was included 53 men observed at The National Medical Research Center for Endocrinology and AZT (n=19) or AZT/HG (n=34) more than 5 years, followed by stimulating gonadotropin therapy. The qualitative parameters of ejaculate were evaluated in all patients. The basic level of statistical significance was pRESULTS: The patient groups were comparable in age, BMI, duration of therapy used, type of testosterone preparation, as well as the etiology of hypogonadism. Sperm concentration in the AZT group there was a statistically significant negative dynamics, while in the ART/HG group, there were no statistically significant differences in the dynamics of sperm concentration. Statistically significant differences in the value of sperm concentration change were revealed. In both groups was observed statistically significant negative dynamics for sperm motility and morphology. There were no statistically significant differences in the value of changes motility and sperm morphology in both studied groups.CONCLUSION: Course combination therapy with testosterone and chorionic gonadotropin is characterized by better results for sperm concentration restoration compared with androgenic replacement therapy. For the restoration of sperm motility and morphology both methods do not show satisfactory results.
- Open Access
- 15 July 2025
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (2) , 31-36
Features of hypogonadism in men with obesity
The relationship between testosterone production and obesity has been found in numerous epidemiological studies. The main feature of obesity in males lies in the fact that it is abdominal obesity, i.e. deposition of adipose tissue mainly in the abdominal area, which has the consequence of affecting sex hormones metabolism. Androgen aromatization, leptin resistance, testosterone deposition, and the influence of other comorbid factors all contribute to the formation of bidirectional relationship between obesity and low testosterone levels. The increased interest in this problem has been observed in recent years, and there is data confirming the link between excess body weight and decreased testosterone levels in males. This latter data is presented in this published review. Meanwhile, reduction of body fat mass can be considered as a proposed approach to correcting hypogonadism associated with metabolic disorders, since hypogonadism in males with metabolic disorders is potentially reversible.
- 15 July 2025
- Published by Endocrinology Research Centre in Bulletin of Reproductive Health
- Vol. 4 (2) , 31-36
Open AccessFeatures of hypogonadism in men with obesity
The relationship between testosterone production and obesity has been found in numerous epidemiological studies. The main feature of obesity in males lies in the fact that it is abdominal obesity, i.e. deposition of adipose tissue mainly in the abdominal area, which has the consequence of affecting sex hormones metabolism. Androgen aromatization, leptin resistance, testosterone deposition, and the influence of other comorbid factors all contribute to the formation of bidirectional relationship between obesity and low testosterone levels. The increased interest in this problem has been observed in recent years, and there is data confirming the link between excess body weight and decreased testosterone levels in males. This latter data is presented in this published review. Meanwhile, reduction of body fat mass can be considered as a proposed approach to correcting hypogonadism associated with metabolic disorders, since hypogonadism in males with metabolic disorders is potentially reversible.
- Open Access
- 24 May 2025
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 22 (1) , 19-25
The frequency and peculiarities of hypogonadism in men with obesity
BACKGROUND: Male hypogonadism is associated with obesity, therefore, it is of interest to study its frequency. The clinical symptoms of hypogonadism are not specific, and laboratory diagnostics is the basis for its detection. The optimal method for this diagnostics is isotope dilution liquid chromatography/tandem mass spectrometry, which was used in our study.AIM: To assess of the incidence and features of hypogonadism in men with obesity.MATERIALS AND METHODS: A full-design, cross-sectional, screening, single-center, non-interventional study of hypogonadal men with obesity, who were treated in Endocrinology Research Centre, Moscow. The study was conducted from January 2023 to May 2024. Medical history assessment, physical examination with determination of body mass index (BMI), measurement estimation of total testosterone by isotope dilution liquid chromatography/tandem mass spectrometry, lipid profiles and uric acid were performed. The groups were compared using the Mann-Whitney U-test for quantitative indicators and χ² with Yates’ correction for qualitative ones. Differences were considered statistically significant with p RESULTS: Hypogonadism was detected in 230 (76,7 (95% CI 71,9–81,5)%) men with obesity. The prevalence of male hypogonadism in overweight was 63,7 (95% CI 53,2–74,3)% of cases, in 1st degree obesity — 74,8 (95% CI 66,8–82,7)%, in 2nd degree obesity — 88,2 (95% CI 76,1–95,6)% and in 3rd degree obesity — 88,9 (95% CI 77,4–95,8)%. Patients with hypogonadism had statistically significantly higher levels of cholesterol, uric acid and triglycerides compared to eugonadal men.CONCLUSION: The prevalence of male hypogonadism in obesity was 76,7 (95% CI 71,9–81,5)%. It was associated with dyslipidemia and hyperuricemia.
- 24 May 2025
- Published by Endocrinology Research Centre in Obesity and metabolism
- Vol. 22 (1) , 19-25
Open AccessThe frequency and peculiarities of hypogonadism in men with obesity
BACKGROUND: Male hypogonadism is associated with obesity, therefore, it is of interest to study its frequency. The clinical symptoms of hypogonadism are not specific, and laboratory diagnostics is the basis for its detection. The optimal method for this diagnostics is isotope dilution liquid chromatography/tandem mass spectrometry, which was used in our study.AIM: To assess of the incidence and features of hypogonadism in men with obesity.MATERIALS AND METHODS: A full-design, cross-sectional, screening, single-center, non-interventional study of hypogonadal men with obesity, who were treated in Endocrinology Research Centre, Moscow. The study was conducted from January 2023 to May 2024. Medical history assessment, physical examination with determination of body mass index (BMI), measurement estimation of total testosterone by isotope dilution liquid chromatography/tandem mass spectrometry, lipid profiles and uric acid were performed. The groups were compared using the Mann-Whitney U-test for quantitative indicators and χ² with Yates’ correction for qualitative ones. Differences were considered statistically significant with p RESULTS: Hypogonadism was detected in 230 (76,7 (95% CI 71,9–81,5)%) men with obesity. The prevalence of male hypogonadism in overweight was 63,7 (95% CI 53,2–74,3)% of cases, in 1st degree obesity — 74,8 (95% CI 66,8–82,7)%, in 2nd degree obesity — 88,2 (95% CI 76,1–95,6)% and in 3rd degree obesity — 88,9 (95% CI 77,4–95,8)%. Patients with hypogonadism had statistically significantly higher levels of cholesterol, uric acid and triglycerides compared to eugonadal men.CONCLUSION: The prevalence of male hypogonadism in obesity was 76,7 (95% CI 71,9–81,5)%. It was associated with dyslipidemia and hyperuricemia.
- 29 April 2025
- Published by Media Sphere Publishing Group in Russian Journal of Human Reproduction
- Vol. 31 (2)
The experience of using the drug Pineamin to improve the quality of ejaculate and reduce the symptoms associated with male aging
Background. In recent years, there has been a continuous scientific search for new drugs to improve fertility and quality of life in men. One of these drugs is Pineamin — a complex of water-soluble polypeptide fractions of the bovine pineal gland, which is evaluated in this study. Objective. To evaluate the dynamics of ejaculate quality indicators and symptoms associated with male aging, against the background of the use of the drug Pineamin in comparison with a competitive intervention — the use of the drug L-carnitine. Material and methods. The pilot multicenter, randomized, parallel-group, interventional, comparative, prospective study included 60 men with pathozoospermia, divided into two comparable groups (Pineamin and L-carnitine). The study period was from May 2023 to December 2024. Spermogram parameters were determined and the AMS questionnaire was administered at baseline and after 3 months of the compared therapy. Results. In the group of patients treated with Pineamin, statistically significant differences were found in all the studied indicators of ejaculate quality before and after therapy. In the group of patients treated with L-carnitine, statistically significant differences were found only in sperm motility. When comparing the values of the changes in the studied parameters between the groups, statistically significant differences were revealed in all the studied indicators of ejaculate quality. The values of the changes in the studied parameters were more pronounced in the Pineamin group, were clinically significant and averaged 24 (95% CI 12; 36) million/ml for concentration, 18 (95% CI 12; 25)% for mobility and 2 (95% CI 1.5; 3.0)% for morphologically normal forms spermatozoa. Changes in the values of the studied parameters in the L-carnitine group were not clinically significant. The decrease in symptoms associated with male aging was statistically significant in the Pineamin group, while this was not observed in the L-carnitine group. Differences between the magnitude of changes in symptoms associated with male aging in the Pineamin and L-carnitine groups are statistically significant. The decrease in symptoms associated with male aging in the Pineamin group was –3 (95% CI –4; –1) points. No adverse events were observed. Conclusions. The use of the drug Pineamin may be promising in the treatment of men with pathozoospermia, as well as the relief of symptoms associated with aging.
- 29 April 2025
- Published by Media Sphere Publishing Group in Russian Journal of Human Reproduction
- Vol. 31 (2)
The experience of using the drug Pineamin to improve the quality of ejaculate and reduce the symptoms associated with male aging
Background. In recent years, there has been a continuous scientific search for new drugs to improve fertility and quality of life in men. One of these drugs is Pineamin — a complex of water-soluble polypeptide fractions of the bovine pineal gland, which is evaluated in this study. Objective. To evaluate the dynamics of ejaculate quality indicators and symptoms associated with male aging, against the background of the use of the drug Pineamin in comparison with a competitive intervention — the use of the drug L-carnitine. Material and methods. The pilot multicenter, randomized, parallel-group, interventional, comparative, prospective study included 60 men with pathozoospermia, divided into two comparable groups (Pineamin and L-carnitine). The study period was from May 2023 to December 2024. Spermogram parameters were determined and the AMS questionnaire was administered at baseline and after 3 months of the compared therapy. Results. In the group of patients treated with Pineamin, statistically significant differences were found in all the studied indicators of ejaculate quality before and after therapy. In the group of patients treated with L-carnitine, statistically significant differences were found only in sperm motility. When comparing the values of the changes in the studied parameters between the groups, statistically significant differences were revealed in all the studied indicators of ejaculate quality. The values of the changes in the studied parameters were more pronounced in the Pineamin group, were clinically significant and averaged 24 (95% CI 12; 36) million/ml for concentration, 18 (95% CI 12; 25)% for mobility and 2 (95% CI 1.5; 3.0)% for morphologically normal forms spermatozoa. Changes in the values of the studied parameters in the L-carnitine group were not clinically significant. The decrease in symptoms associated with male aging was statistically significant in the Pineamin group, while this was not observed in the L-carnitine group. Differences between the magnitude of changes in symptoms associated with male aging in the Pineamin and L-carnitine groups are statistically significant. The decrease in symptoms associated with male aging in the Pineamin group was –3 (95% CI –4; –1) points. No adverse events were observed. Conclusions. The use of the drug Pineamin may be promising in the treatment of men with pathozoospermia, as well as the relief of symptoms associated with aging.